Enclomiphene: the useful half of clomiphene, without the half that lingers

Clomiphene citrate is a mixture. One isomer does the work and clears in hours; the other lingers for weeks and carries most of the complaints. Enclomiphene is the first one on its own — a clean idea whose regulatory story is anything but.

Why isolating it makes sense

Established clinical use Clomiphene citrate contains two geometric isomers. Enclomiphene, the trans isomer, is the antioestrogen at the hypothalamus: blocking oestrogen receptors there removes the brake on GnRH, so LH and FSH rise and the testis produces more testosterone. Zuclomiphene, the cis isomer, has oestrogenic activity and a half-life measured in days to weeks rather than hours, so it accumulates over sustained daily use.

That accumulation is the most likely explanation for effects that appear after several weeks on clomiphene rather than at the start — mood changes among them — and it is the entire rationale for the purified product. The app models enclomiphene at about ten hours against clomiphene’s blended five-day figure, and that difference is the zuclomiphene being gone rather than a change in what the active isomer does.

The mechanism is worth stating clearly because it is structurally different from testosterone therapy. LH and FSH rise rather than fall, testicular volume is preserved, and spermatogenesis is preserved or improved — which is why it is discussed as an option for men who want testosterone restored without losing fertility. It also means it only works if the pituitary and the testis can respond, so it does nothing for primary testicular failure. The LH and FSH page covers how that distinction is made.

The regulatory position, stated plainly

Off-label or community practice Enclomiphene is not approved. A new drug application was filed and did not result in an approval, and what is available in the United States comes from compounding pharmacies. That places it in an awkward category: it is not a research chemical in the sense that most of this site’s Tier B compounds are — it has been through clinical trials in the intended population and the trial results are published — but it also has no approved product behind it, and no regulator has signed off on any particular preparation.

The practical consequence is the usual one. Identity, purity and content rest with the compounder, and there is no reference product to compare against. This site names no pharmacy and no testing service.

What it will and will not do

Off-label or community practice The trials reported testosterone rising into the normal range with sperm concentration preserved, which is the combination testosterone therapy cannot offer. What they did not show is testosterone reaching the levels people commonly target on testosterone therapy: this raises your own production within what your own axis can do, and for some men that ceiling is lower than they were hoping for. Setting that expectation before starting avoids a lot of disappointment.

Estradiol is the number to watch alongside it. Raising testosterone raises the substrate for aromatisation, and a SERM blocking receptors in the hypothalamus does not stop circulating estradiol rising elsewhere. The measured value and the receptor-level effect can move in different directions, which is exactly why the number alone does not settle anything — and why the assay has to be a sensitive one. The estradiol page covers that.

Visual disturbance is the effect from this drug class with a conventional instruction attached: blurring or persistent after-images are a reason to stop and contact the prescriber rather than continue and monitor. Everything else on the drawbacks list below belongs in the same conversation. The clomiphene page covers the parent compound.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: Enclomiphene half-life and steady state.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Enclomiphene, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Total testosterone
• Free versus total testosterone, and the three ways labs get the free number
• LH and FSH

Drawbacks and risks the app records

From the app’s own entry. Note that most of these are about availability and evidence rather than about tolerability — which is the accurate picture for this one.

• Smaller body of evidence than standard Clomid
• Not FDA approved (Androxal trials completed but approval pending)
• Sourcing may be from compounding pharmacies
• Long-term effects on testicular health not fully studied
• Does not work in primary hypogonadism (testicular failure)
• Still more expensive than standard Clomid
• Cannot achieve testosterone levels as high as TRT
• Daily oral medication
• Less available than Clomid
• Insurance typically does not cover
• Requires intact HPG axis

Questions people actually ask

Is it better than clomiphene?

It removes the isomer that accumulates and carries most of the complaints, which is a coherent rationale and the reason it was developed separately. It is also less available, not approved, and compounded. Which of those matters more is a prescribing conversation.

Does it work in primary hypogonadism?

No. It works by raising the pituitary signal, so it requires a testis able to respond. Where the testis itself is the problem, stimulating harder achieves little — which is what LH and FSH are measured to establish before starting.

How high will testosterone go?

Into the normal range in the trials, not to the levels commonly targeted on testosterone therapy. It raises what your own axis can produce, and that ceiling is individual.

How long before labs are meaningful?

LH and FSH respond within days, testosterone over two to four weeks. Without zuclomiphene accumulating in the background, an assessment at six weeks is measuring a settled state — which is one practical advantage over the parent compound.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.